Wednesday, March 25th
9:15-10:15 AM PT
Room 24B
The changing pharmaceutical environment is delaying definitive nonclinical and clinical testing to after Phase IIB. Yet increasing regulatory requirements force organizations to look for alternative development plans. Learn how connections between toxicology and metabolism can help to de-risk your programs and blaze a path forward.
Presented by:
Head of In Vitro/Ex Vivo Study Direction
Executive Director, Global Drug Metabolism
